COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Up 6.7% in April

COMPASS Pathways plc (NASDAQ:CMPS) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,340,000 shares, a growth of 6.7% from the March 31st total of 3,130,000 shares. Based on an average daily trading volume, of 705,600 shares, the short-interest ratio is currently 4.7 days.

Wall Street Analyst Weigh In

CMPS has been the subject of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of COMPASS Pathways in a research report on Friday, March 1st. Finally, Morgan Stanley started coverage on COMPASS Pathways in a research report on Monday, April 1st. They set an “overweight” rating and a $30.00 price target on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $47.40.

Insider Buying and Selling

In other COMPASS Pathways news, Director George Jay Goldsmith sold 15,740 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $10.58, for a total value of $166,529.20. Following the completion of the transaction, the director now directly owns 4,079,107 shares of the company’s stock, valued at approximately $43,156,952.06. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Ekaterina Malievskaia sold 19,853 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total transaction of $210,243.27. Following the completion of the transaction, the director now directly owns 4,144,994 shares in the company, valued at approximately $43,895,486.46. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $10.58, for a total transaction of $166,529.20. Following the completion of the sale, the director now owns 4,079,107 shares of the company’s stock, valued at approximately $43,156,952.06. The disclosure for this sale can be found here. Insiders have sold 140,601 shares of company stock valued at $1,338,911 in the last quarter. Company insiders own 4.25% of the company’s stock.

Institutional Trading of COMPASS Pathways

Hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC increased its stake in shares of COMPASS Pathways by 7.6% in the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock valued at $22,915,000 after purchasing an additional 186,040 shares during the period. Bank of New York Mellon Corp bought a new position in COMPASS Pathways in the 3rd quarter worth approximately $597,000. Armistice Capital LLC acquired a new stake in COMPASS Pathways in the 3rd quarter valued at approximately $2,960,000. Vivo Capital LLC bought a new stake in COMPASS Pathways during the 3rd quarter valued at $11,899,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in COMPASS Pathways by 4.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 110,939 shares of the company’s stock worth $971,000 after acquiring an additional 4,981 shares during the period. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Stock Down 1.1 %

Shares of CMPS stock opened at $8.48 on Thursday. The business has a 50 day moving average of $9.57 and a two-hundred day moving average of $8.46. COMPASS Pathways has a 52 week low of $5.01 and a 52 week high of $12.75. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). As a group, equities analysts predict that COMPASS Pathways will post -2.4 earnings per share for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.